Efficacy of 1400 W, a novel inhibitor of inducible nitric oxide synthase, in preventing interleukin-1β-induced suppression of pancreatic islet function in vitro and multiple low-dose streptozotocin-induced diabetes in vivo

European Journal of Endocrinology

Volumn 147, Issue 4, 2002, Pages 543-551

  Rydgren, Tobias ^a   Sandler, Stellan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLUCOSE; INSULIN; LIPOPOLYSACCHARIDE; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; NITRATE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; RECOMBINANT INTERLEUKIN 1BETA; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INSULIN SYNTHESIS; INSULITIS; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

EID: 0036773013     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1470543     Document Type: Article

References (35)

1. Bach J. Insulin-dependent diabetes mellitus as a β-cell targeted disease of immunoregulation. Journal of Autoimmunity 1995 8 439-463.
2. Alderton WK, Cooper CE & Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochemical Journal 2001 357 593-615.
3. Förstermann U, Gath I, Schwarz P, Closs EI & Kleinert H. Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Biochemical Pharmacology 1995 50 1321-1332.
4. Kolb H & Kolb-Bachofen V. Type 1 (Insulin dependent) diabetes mellitus and nitric oxide. Diabetologia 1992 35 796-797.
5. Corbett JA & McDaniel ML. Does nitric oxide mediate autoimmune destruction of β-cells? Diabetes 1992 41 897-903.
6. Wink D & Mitchell JB. Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radical Biology and Medicine 1998 25 434-456.
7. Corbett JA & McDaniel ML. Intraislet release of interleukin 1 inhibits β cell function by inducing β cell expression of inducible nitric oxide synthase. Journal of Experimental Medicine 1995 181 559-568.
8. Eizirik DL, Sandler S, Welsh N, Cetkovic-Cvrlje M, Nieman A, Geller DA et al. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. Journal of Clinical Investigation 1994 93 1968-1974.
9. Rabinovitch A, Suarez-Pinzon W Sorensen O & Bleackley RC. Inducible nitric oxide synthase (iNOS) in pancreatic islets of non-obese diabetic mice: identification of iNOS expressing cells and relationships to cytokines expressed in the islets. Endocrinology 1996 137 2093-2099.
10. Kleemann R, Rothe H, Kolb-Bachofen V, Me Q, Nathan CN, Martin S et al. Transcription and translation of inducible nitric oxide synthase in the pancreas of prediabetic BB rats. FEBS Letters 1993 328 9-12.
11. Flodström M, Tyrberg B, Eizirik DL & Sandler S. Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes. Diabetes 1999 42 706-713.
12. Suarez-Pinzon WL, Mabley JG, Strynadka K, Power RF, Szabo C & Rabinovitch A. An inhibitor of inducible nitric oxide synthase and scavenger of peroxynitrite prevents diabetes development in NOD mice. Journal of Autoimmunity 2001 16 449-455.
13. Garvey EP, Oplinger JA, Furfine ES, Kiff RJ, Laszlo F, Whittle BJR et al. 1400 W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. Journal of Biological Chemistry 1997 272 4959-4963.
14. 15N]nitrate in biological fluids. Analytical Biochemistry 1982 126 131-138.
15. Hinegardner RT. An improved fluorometric assay for DNA. Analytical Biochemistry 1971 39 197-201.
16. Halban PA, Wollheim CB, Blondel B & Renold AE. Long-term exposure of isolated pancreatic islets to mannoheptulose: evidence for insulin degradation in the β-cell. Biochemical Pharmacology 1980 29 2625-2633.
17. Parmentier S, Böhme GA, Lerouet D, Damour D, Stutzmann J-M, Margaill I et al. Selective inhibition of inducible nitric oxide synthase prevents ischaemic brain injury. British Journal of Pharmacology 1999 127 546-552.
18. Sandler S & Andersson A. Modulation of streptozotocin-induced insulitis and hyperglycaemia in the mouse. Acta Pathologica, Microbiologica et Immunologica Scandinavica. Section A, Pathology 1985 93 93-98.
19. Rabinovitch A, Suarez-Pinzon W, Strynadka K, Schulz R, Lakey JR, Warnock GL et al. Human pancreatic islet β-cell destruction by cytokines is independent of nitric oxide production. Journal of Clinical Endocrinology and Metabolism 1994 79 1058-1062.
20. Dunger A, Cunningham JM, Delaney CA, Lowe JE, Green MH, Bone AJ et al. Tumor necrosis factor-alpha and interferon-gamma inhibit insulin secretion and cause DNA damage in unweaned rat islets. Extent of nitric oxide involvement. Diabetes 1996 45 183-189.
21. Andersson AK, Flodström M & Sandler S. Cytokine-induced inhibition of insulin release from mouse pancreatic β-cells deficient in inducible nitric oxide synthase. Biochemical and Biophysical Research Communications 2001 281 396-403.
22. Mandrup-Poulsen T, Corbett JA, McDaniel ML, & Nerup J. What are the types and cellular sources of free radicals in the pathogenesis of type 1 (insulin dependent) diabetes mellitus? Diabetologia 1993 36 470-471.
23. Papaccio G, Pisanti FA, Latronico MV, Ammendola E & Galdieri M. Multiple low-dose and single high-dose treatments with streptozotocin do not generate nitric oxide. Journal of Cellular Biochemistry 2000 77 82-91.
24. Lukic ML, Stosic-Grujicic S, Ostojic N, Chan WL & Liew FY Inhibition of nitric oxide generation affects the induction of diabetes by streptozotocin in mice. Biochemical and Biophysical Research Communications 1991 178 913-920.
25. Kolb H, Kiesel U, Kröncke K-D & Kolb-Bachofen V. Suppression of low dose streptozotocin induced diabetes in mice by administration of a nitric oxide synthase inhibitor. Life Sciences 1991 49 PL213-PL217.
26. Papaccio G, Esposito V, Latronico MV & Pisanti FA. Administration of a nitric oxide synthase inhibitor does not suppress low-dose streptozotocin-induced diabetes in mice. International Journal of Pancreatology 1995 17 63-68.
27. Holstad M & Sandler S. Aminoguanidine, an inhibitor of nitric oxide formation, fails to protect against insulitis and hyperglycemia induced by multiple low dose streptozotocin injections in mice. Autoimmunity 1993 15 311-314.
28. G-monomethyl-L-arginine on the onset of diabetes in the spontaneously diabetic BB rat. Diabetes 1995 44 360-364.
29. ω-nitro-L-arginine methyl ester reduces the incident of IDDM in BB/E rats. Diabetes 1995 44 365-368.
30. Corbett JA, Mikhael A, Shimizu J, Frederick K, Misko TP, McDaniel ML et al. Nitric oxide production in islets of nonobese diabetic mice: aminoguanidine-sensitive and -resistant stages in the immunological diabetic process. PNAS 1993 90 8992-8995.
31. Bowman M, Simell O. Look Z, Luchetta R & Atkinson M. Pharmacokinetic and therapeutic analysis of aminoguanidine (AG) in non-obese diabetic (NOD) mice. Diabetes 1994 43 (Suppl. 1) 235A.
32. Welsh M, Welsh N, Bendtzen K, Mares J, Strandell E, Öberg C et al. Comparison of mRNA contents of interleukin-1β and nitric oxide synthase in pancreatic islets isolated from female and male nonobese diabetic mice. Diabetologia 1995 38 153-160.
33. Rabinovitch A, Suarez-Pinzon WL, Sorensen O & Bleackley RC. Inducible nitric oxide synthase (iNOS) in pancreatic islets of non-obese diabetic mice: identification of iNOS-expressing cells and relationships to cytokines expressed in the islets. Endocrinology 1996 137 2093-2099.
34. McMillan K, Adler M, Auld DS, Baldwin JJ, Blasko E, Browne LJ et al. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. PNAS 2000 97 1506-1511.
35. Eizirik DL, Pipeleers DG, Ling Z, Welsh N, Hellerström C & Andersson A. Major species differences between humans and rodents in the susceptibility to pancreatic β-cell injury. PNAS 1994 91 9253-9256.